China NMPA approves IND for KPG-818 in relapsed or refractory MM
The Center for Drug Evaluation of the China National Medical Products Administration (NMPA) approved the IND application for KPG-818.
Multiple Myeloma
Acute Lymphoblastic Leukemia
News
Nanobody-based CD7 CAR-T induces responses in patients with AML in early-phase study
A phase 1 study found that “naturally selected” CD7 chimeric antigen receptor T-cell (NS7CAR-T) therapy was well-tolerated and induced complete responses (CRs) in
Society Updates
Ask the lymphoma expert: Dr. Maddocks
Have a burning question about a patient with B-cell malignancies for Hodgkin or non-Hodgkin lymphoma? Ask Kami Maddocks, MD, professor in the College
Cellular Therapy
Lymphoma
News
Risk factors for manufacturing failure, associated outcomes in patients receiving CAR-T for LBCL
Researchers found that prior use of bendamustine within six months of apheresis was the only baseline variable associated with a risk of manufacturing
Cellular Therapy
Multiple Myeloma
Patient case highlights secondary tumor after CAR-T treatment for myeloma
A case study of a 63-year-old male with early relapse of multiple myeloma (MM) indicated that treatment with a chimeric antigen receptor (CAR)
Leukemia
Lymphoma
Long-term use of TNF inhibitors for psoriasis may increase risk for certain blood cancers
A study assessed the risk of cancer in patients receiving long-term treatment with tumor necrosis factor (TNF)-alpha inhibitors and found that cumulative use
Multiple Myeloma
Combination monoclonal antibody treatment induces responses but also infections in MM
In a phase 1b/2 study, researchers assessed the feasibility of combining talquetamab and teclistamab for the treatment of relapsed or refractory multiple myeloma
Multiple Myeloma
A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients
The combination of isatuximab, bortezomib, and lenalidomide with limited dexamethasone is a feasible treatment option for transplant-ineligible older patients with multiple myeloma (MM),
Lymphoma
News
Interim PET scan after 4 treatment cycles predicts outcomes in primary mediastinal B-cell lymphoma patients
An interim positron emission tomography (PET) scan after four treatment cycles emerged as the strongest predictor of outcomes for primary mediastinal B-cell lymphoma
Lymphoma
FDA clears Ventana hematopathology test for diagnosing BCL
The US Food and Drug Administration (FDA) has granted clearance to the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an in-situ
